Market Overview

Bluebird News A Positive For Juno, Kite Pharma

Bluebird News A Positive For Juno, Kite Pharma
Related BLUE
12 Biggest Mid-Day Losers For Friday
20 Stocks Moving In Friday's Pre-Market Session
Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone (Investor's Business Daily)
Related CELG
Dow 30 Stock Roundup: Boeing Bags Big Orders at Paris Air Show; Wal-Mart to Buy Bonobos
Benzinga's Option Alert Recap From June 21
Too Late To Catch Biotech Rally As Trump Fears Subside? (Investor's Business Daily)

Citi’s Robyn Karnauskas said the positive early stage cancer study results from bluebird bio Inc (NASDAQ: BLUE) is positive for CAR-T space and B-cell maturation antigen (BMCA) drugs of Juno Therapeutics Inc (NASDAQ: JUNO) and Kite Pharma Inc (NASDAQ: KITE).

Chimeric antigen receptors (CARs) are proteins that allow the T cells to recognize a specific protein (antigen) on tumor cells. BCMA is a suitable target for CAR-expressing T cells, and adoptive transfer of anti-BCMA-CAR-expressing T cells is a promising new strategy for treating multiple myeloma.

Cambridge, Massachusetts-based bluebird bio said early data from its ongoing Phase 1 study of bb2121 showed objective anti-tumor responses in heavily pre-treated multiple myeloma patients. Bluebird bio is developing bb2121 in collaboration with Celgene Corporation (NASDAQ: CELG).

Study Highlights

Following are the key highlights of the study:

  • In highly refractory multiple myeloma, bb2121 shows 78 percent overall response rate (ORR), including 100 percent ORR at higher doses tested.
  • bb2121 appears safe, with no DLTs or serious cases of cytokine release syndrome (CRS) or neurotoxicity observed.
  • Safety profile was achieved with no anti-IL6/steroid treatment.

Beyond The Blue

Given the safety profile, the results are likely to boost investor confidence in CAR-T, following Juno Therapeutics' recent clinical hold due to neuro-toxicity related deaths.

Importantly, the analyst noted that bluebird's BCMA success is also a positive read-through for Juno and Kite Pharma as both are developing their own BCMA drugs for multiple myeloma and other B-cell malignancies.

“Though we note that the data is still early, we believe that Bluebird's success provides clinical validation for using BCMA to target multiple myeloma,” Karnauskas wrote in a note.

While Kite Pharma is expected to file IND for their fully-human KITE-585 in 2017, Juno expects to be in clinic as early as first half of 2017.

At last check, shares of bluebird surged 15.70 percent to $69.82. Meanwhile, Juno Therapeutics were up 0.25 percent to $20.10, while Kite Pharma fell 0.68 percent to $50.58.

Latest Ratings for BLUE

Jun 2017Standpoint ResearchDowngradesBuyReduce
Jun 2017BMO CapitalUpgradesMarket PerformOutperform
May 2017Standpoint ResearchInitiates Coverage OnBuy

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Analyst Ratings Movers Trading Ideas General Best of Benzinga


Related Articles (CELG + BLUE)

View Comments and Join the Discussion!